Summary:
In rats with streptozotocin (STZ) induced diabetes the effect of (watersoluble) thiamine nitrate and of (lipidsoluble) benfotiamine on peripheral nerve function (motor nerve conduction velocity) as well as on the formation of advanced glycation end-products in peripheral nerve tissue was studied. In one group of animals drug administration was started immediately after diabetes induction (prevention study) and in another group two months after diabetes induction (treatment study). Motor nerve conduction velocity (NCV) dropped by 10.5% in diabetic animals, carboxymethyl-lysine (CML) rose to a 3.5fold concentration, deoxyglucosone (3DG)-type AGE formation was increased 5.1fold compared with controls. After three months preventive administration of both vitamin B1 preparations NCV had increased substantially compared with results in diabetic controls. It was nearly normal after six months with benfotiamine, while the administration of thiamine nitrate resulted in no further amelioration. NCV was nearly normalized after six months of benfotiamine application but not with thiamine. Furthermore, benfotiamine induced a major inhibition of neural imidazole-type AGE formation and completely prevented diabetes induced glycoxidation products (CML). Treatment with thiamine did not significantly affect AGE or cmL levels. Unlike treatment with water-soluble thiamine nitrate timely administration of liposoluble prodrug benfotiamine was effective in the prevention of functional damage and of AGE and cmL formation in nerves of diabetic rats.
Key words:
Diabetic (STZ) rats - nerve conduction velocity - nerve glycoxidation products - benfotiamine protection
References
1
Becker K W, Kienecker E-W, Dick P.
A contribution to the scientific assessment of degenerative and regenerative processes in peripheral nerve fibers following axonotmesis under the systemic administration of vitamin B1 , B6 and B12 - light and electron microscopy findings in the saphenous nerve of the rabbit.
Neurochirurgia.
33
113-121
1990;
2
Bitsch R, Wolf M, Müller J, Heuzeroth L, Grüneklee D.
Bioavailability assessment of the lipophile benfotiamine compared to a water-soluble thiamine derivative.
Hum Nutr Metab.
35
292-296
1991;
3 Bitsch J, Netzel M, Ziems M, Wenisch S. Untersuchungen zur neuroprotektiven Wirkung von Benfotiamin. In: Gries FA, Federlin K (Hrsg.) Benfotiamin in der Therapie von Polyneuropathien. Int. Sympos. Stuttgart. Thieme-Verlag : 35-39 1998
4
Both A A, Khalifah R G, Hudson B G.
Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
Biochem Biophys Res Comm.
220
113-119
1996;
5
Burnard S L, McMurchie E J, Leifert W R, Patten G S, Muggli R, Raederstorff D, Head R J.
Cilazapril and dietary gamma-linolenic acid prevent the deficit in sciatic nerve conduction velocity in the streptozotocin diabetic rat.
J Diab Comp.
12
65-73
1998;
6
Haupt E, Ledermann H, Köpcke W.
Benfotiamine in treatment of diabetic neuropathy.
J Periph Nerv Syst.
2
270
1997;
7
Horiuchi S, Araki N, Morino Y.
Immunochemical approach to characterize advanced glycation end-products of the Maillard reaction. Evidence for the presence of a common structure.
J Biol Chem.
266(12)
7329-7332
1991;
8
Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S.
N(epsilon)-carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end-products of the Maillard reaction.
Biochemistry.
35
8075-8083
1996;
9
Jermendy G, Noll E, Perényi J, Dworschak E.
Thiamine status in NIDDM patients with somatic neuropathy.
Diabetologia
40
((Suppl 1))
A 561
1997;
10
LaSilva M, Beltramo E, Pagnozzi F, Bena E, Molinatti P A, Molinatti G M, Porta M.
Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions.
Diabetologia.
39
1262-1268
1996;
11
Ledermann H, Wiedey K D.
Behandlung der manifesten diabetischen Polyneuropathie. Therapeutische Wirkung des neurotropen Vitamin-B-Komplexes B1 -B6 -B12 .
Therapiewoche.
39
1445-1449
1989;
12 Netzel M. Zur Verfügbarkeit, Metabolisierung und Wirkung von S-Benzoylthiamin-O-Monophosphat während und nach einer chronischen Äthanolzufuhr. Untersuchungen am Tiermodell Inaugural-Dissertation, Universität Giessen. Wiss. Fachverlag Giessen 1997
13
Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y.
Immunohistochemical detection of imidazolone, a novel advanced glycation end-product, in kidneys and aortas of diabetic patients.
J Clin Invest.
99
1272-1280
1997;
14
Reiners K H, Haupt S.
Die Wirkung der Vitamine B1, B6 und B12 auf den Einbau von Cholin in den Ischiasnerv des Kaninchens.
Vitaminspur.
11
74-84
1996;
15
Schreeb K H, Freudenthaler S, Vormfelde S V, Gundert-Remy U, Gleiter C H.
Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate.
Eur J Clin Pharmacol.
52
319-320
1997;
16
Sima A AF, Sugimoto K.
Experimental diabetic neuropathy: an update.
Diabetologia.
42
773-788
1999;
17
Stracke H, Lindemann A, Federlin K.
A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.
Exp Clin Endocrinol Diabetes.
104
311-316
1996;
18
Vlassara H, Brownlee M, Cerami A.
Nonencymatic glyocosylation of peripheral nerve protein in diabetes mellitus.
Proc Natl Acad Sci USA.
78
5190-5192
1981;
19
Vlassara H, Brownlee M, Cerami A.
Excessive nonencymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats.
Diabetes.
32
670-674
1983;
20
Ziems M, Netzel M, Rampach C, Jaworski A, Bitsch I.
Untersuchungen zur Biokinetik des Benfotiamins beim Menschen.
Zeitschr f Ernährungswiss.
35
95-96
1995;
21 Ziems M. Zur Biokinetik des S-Benzoylthiamin-O-Monophosphats bei gesunden Männern. Analyse mit Metaboliten-Modellen Inaugural-Dissertation, Universität Giessen, Wiss. Fachverlag Giessen 1997
Prof. Dr. H. Stracke
Center of Internal Medicine
Department of Endocrinology and Metabolism
University of Giessen
Rodthohl 6
D-35385 Giessen
Germany
Phone: +49-641-99-42754
Fax: +49-641-99-42769
Email: Hilmar.Strackeinnere.med.uni-giessen.de